New Push for Affordable Health Care Drugs
President Trump’s health advisors announced an initiative to reduce health care costs by increasing the availability of innovative generic drugs during a press conference on Wednesday.
The Food and Drug Administration (FDA) revealed plans to clear bureaucratic obstacles that currently protect its monopoly on biologics, many of which are among the most expensive medications available.
FDA Commissioner Marty McCulley noted that biologics—medications derived from living organisms—mark a significant advancement in biotechnology. He pointed out that a single treatment can run into millions, leaving patients facing high costs without insurance at a severe disadvantage.
The new initiative is aimed at promoting the creation of biosimilars, which are generic versions of biological drugs.
“There’s hardly any competition in the pharmaceutical market. We’re not even supposed to discuss it. The pharmaceutical industry is extremely protected,” McCurry remarked.
Although the details of the policy remain somewhat unclear, health officials emphasized that it is essential for the financial well-being of average Americans.
“We’re swapping out red tape for scientific advancement, monopoly power for competition, and hopelessness for optimism,” President Kennedy added.
High costs associated with these medications can burden federal health programs significantly. Interestingly, while biologics account for only 5% of prescriptions in the U.S., they represent over half of total drug expenditures. Concerns have risen regarding costly biologics approved by the FDA, which may result in Medicare and Medicaid expenses soaring into the billions for just one drug.
Mehmet Oz, head of the Centers for Medicare and Medicaid Services, urged states to facilitate Medicaid funding by adopting more biosimilars.
This report arrives amid an ongoing government impasse regarding health care affordability, where Republicans and Democrats are split on issues like extending Medicaid coverage to undocumented immigrants and prolonging health insurance subsidies from the pandemic era.
“The area of fastest growth in U.S. healthcare spending is on drugs. Within that, biologics are the fastest-growing category,” McCurry stated.
The FDA has introduced new draft guidance intended to clarify what research drug companies must conduct for biosimilar drugs. This change aims to eliminate unnecessary studies, categorizing more biosimilars as interchangeable with their brand-name counterparts. This adjustment, as per HHS, should ease the process for patients seeking less expensive generic drugs.
When asked about the potential for antitrust actions against the industry, McCulley did not provide a direct answer.
Kennedy highlighted that the existing bureaucracy stems from lobbying efforts by biologics manufacturers that deter healthy competition.
According to the Biosimilars Forum, this overhaul could lead to a considerable reduction in the costs associated with bringing biosimilars to market. Generally, the development of a biosimilar can cost between $100 million to $300 million and typically takes six to nine years.
“Biosimilars could save an additional $181 billion over the next five years,” stated Julianna M. Reed, executive director of the Biosimilars Forum. “These savings are achievable only through sensible policy adjustments like those we’re implementing today.”
Health Department Secretary Robert F. Kennedy Jr. commented that European regulators approved significantly more biosimilars than the FDA last year. Since the FDA established the biosimilar approval process in 2015, only 76 biosimilars have received approval in the U.S., whereas a truly competitive market might see two to three times that number.
Even though biosimilars are priced about half of their branded counterparts, they hold a market share of less than 20% and haven’t yet gained widespread acceptance. One study indicated that a mere one-third of the $500 million in sales of biologic drugs is moving toward generic development.
McCurry mentioned that branded biologic manufacturers can sometimes mislead drug benefit managers to maintain their market position.
The Pharmaceutical Research and Manufacturing Association (PhRMA), representing branded drug makers, condemned the practices of pharmacy benefit managers (PBMs).
“The key issue in the biosimilar market is that PBMs are sidelining low-cost generic drugs and biosimilars from insurance coverage, which ultimately drives drug costs higher for Americans and stifles competition,” stated Alex Schreiber, PhRMA’s senior vice president of public affairs. “Policymakers must intervene to address the disproportionate incentives and practices that prioritize profits at patients’ expense.”
Schreiber also noted a significant increase in the number of biosimilars excluded from at least one major PBM formulary since 2022.
